Evidence map›Paper›PMID 31759486›Full record

ArticleKidney international2019

Ferric citrate: cardio- and renoprotective in chronic kidney disease?

Mark R Hanudel

Abstract readComment
PubMed Publisher
In one paragraph

Article in Kidney international, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 80% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Mark R HanudelDepartment of Pediatrics, Division of Nephrology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California, USA. Electronic address: mhanudel@mednet.ucla.edu.
University of California, Los Angeles · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Ferric citrate is a phosphate binder that may also be used to treat iron-deficiency anemia. In human studies, ferric citrate treatment in the setting of chronic kidney disease has been associated with effective phosphate control, improved iron and hematologic parameters, and decreased fibroblast growth factor 23 levels. In the present study, mice with chronic kidney disease treated with ferric citrate have similarly improved biochemical profiles, but also have improved cardiac and renal function and prolonged survival.

Indexed as

Anemia, Iron-DeficiencyRenal Insufficiency, ChronicAnimalsFerric CompoundsFibroblast Growth Factor-23Fibroblast Growth FactorsHumansMiceferric citrateFerric CompoundsFibroblast Growth Factor-23Fibroblast Growth Factors

Identifiers

PMID31759486
OpenAlexW2990459802

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.